Biswajit Dash
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Biswajit Dash has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
- Allen Gideon Tan
Department of Obstetrics and Gynecology, University of the Philippines Manila, Manila, Philippines
3 shared publications - Angela Cho
Department of Obstetrics and Gynecology, Jeju National University Hospital, Jeju National University College of Medicine, Jeju, Korea
3 shared publications - Christine Shan-Chi Chiu
Department of Obstetrics and Gynecology, Mackay Memorial Hospital, Taipei, Taiwan
3 shared publications - Doris R. Benavides
Department of Obstetrics and Gynecology, University of the Philippines Manila, Manila, Philippines
3 shared publications - Emiri Miyamoto
Department of Obstetrics and Gynecology, Nagoya University Graduate School of Medicine, Nagoya, Japan
3 shared publications - Geon Woo Lee
Department of Obstetrics and Gynecology, Chungnam National University Hospital, Daejeon, Korea
3 shared publications
Latest Publications
- Open Access
- 1 January 2027
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 38
Current status of fertility preservation for borderline ovarian tumor in Asian regions: results from ASGO-special task force for fertility preservation; part I. Fertility-sparing treatment for borderline ovarian tumor
Kuji S, et al. J Gynecol Oncol. 2027 ;38:e24. https://doi.org/10.3802/jgo.2027.38.e24
- 1 January 2027
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 38
Open AccessCurrent status of fertility preservation for borderline ovarian tumor in Asian regions: results from ASGO-special task force for fertility preservation; part I. Fertility-sparing treatment for borderline ovarian tumor
Kuji S, et al. J Gynecol Oncol. 2027 ;38:e24. https://doi.org/10.3802/jgo.2027.38.e24
- Open Access
- 1 January 2027
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 38
Current status of fertility preservation for borderline ovarian tumor in Asian countries: results from ASGO-special task force for fertility preservation; part II. Fertility and pregnancy planning following initial treatment
Kuji S, et al. J Gynecol Oncol. 2027 ;38:e21. https://doi.org/10.3802/jgo.2027.38.e21
- 1 January 2027
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 38
Open AccessCurrent status of fertility preservation for borderline ovarian tumor in Asian countries: results from ASGO-special task force for fertility preservation; part II. Fertility and pregnancy planning following initial treatment
Kuji S, et al. J Gynecol Oncol. 2027 ;38:e21. https://doi.org/10.3802/jgo.2027.38.e21
- Open Access
- 1 January 2027
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 38
The real-world practice of fertility preservation for patients with epithelial ovarian cancer in Asian regions
Yoshihara M, et al. J Gynecol Oncol. 2027 ;38:e17. https://doi.org/10.3802/jgo.2027.38.e17
- 1 January 2027
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 38
Open AccessThe real-world practice of fertility preservation for patients with epithelial ovarian cancer in Asian regions
Yoshihara M, et al. J Gynecol Oncol. 2027 ;38:e17. https://doi.org/10.3802/jgo.2027.38.e17
- Open Access
- 31 December 2024
- Published by Springer Nature in Indian Journal of Gynecologic Oncology
- Vol. 23 (1) , 1-10
Variations in the Management of Low-Grade Serous Carcinoma of the Ovary: A Global Survey
Objective: Low-grade serous carcinoma (LGSOC) constituting < 15% of ovarian or peritoneal serous carcinomas differs distinctly from high-grade serous ovarian carcinoma (HGSOC). This global survey investigates the variations in managing LGSOC, acknowledging its unique characteristics and the absence of a consensus on optimal management. Methods: A voluntary non-incentivized global survey gathered responses from 203 practitioners across 50 countries and 7 continents. Approved by the Institutional Ethics Committee, it encompassed 21 questions focusing on demographics, diagnosis, and management practices. Descriptive statistics and Fisher’s exact test analyzed the data. Results: Demographically diverse responses were obtained with the majority from India (39.9%) and Colombia (5.4%). Gynecologic oncologists predominated (73.10%), with varied practice settings. Most practitioners considered LGSOC distinct (95.57%). Diagnosis criteria showed institutional variations. In managing apparent inoperable stage III C LGSOC approaches varied: neoadjuvant chemotherapy (54.78%), upfront surgery (35.69%), and neoadjuvant hormone therapy (8.54%). Adjuvant management demonstrated heterogeneity. Notably, there was no significant association between the continent and the offered adjuvant treatment for optimally cytoreduced stage III C LGSOC (p = 0.556; Fisher’s exact test). For recurrent disease, hormonal therapy (30.54%) and chemotherapy (27.59%) were common choices. MEK inhibitors were infrequently used. Fertility preservation was favored (71%), and HIPEC was not widely considered (81.28%). Genetic testing opinions varied: routine testing (28.7%), no recommendation (45.32%), and testing in recurrent settings (16.75%). Conclusion: This survey exposes global disparities in LGSOC management, highlighting the need for standardized guidelines to address challenges in diagnosis and management. International collaboration is advocated to enhance uniformity in healthcare practices for LGSOC.
- 31 December 2024
- Published by Springer Nature in Indian Journal of Gynecologic Oncology
- Vol. 23 (1) , 1-10
Open AccessVariations in the Management of Low-Grade Serous Carcinoma of the Ovary: A Global Survey
Objective: Low-grade serous carcinoma (LGSOC) constituting < 15% of ovarian or peritoneal serous carcinomas differs distinctly from high-grade serous ovarian carcinoma (HGSOC). This global survey investigates the variations in managing LGSOC, acknowledging its unique characteristics and the absence of a consensus on optimal management. Methods: A voluntary non-incentivized global survey gathered responses from 203 practitioners across 50 countries and 7 continents. Approved by the Institutional Ethics Committee, it encompassed 21 questions focusing on demographics, diagnosis, and management practices. Descriptive statistics and Fisher’s exact test analyzed the data. Results: Demographically diverse responses were obtained with the majority from India (39.9%) and Colombia (5.4%). Gynecologic oncologists predominated (73.10%), with varied practice settings. Most practitioners considered LGSOC distinct (95.57%). Diagnosis criteria showed institutional variations. In managing apparent inoperable stage III C LGSOC approaches varied: neoadjuvant chemotherapy (54.78%), upfront surgery (35.69%), and neoadjuvant hormone therapy (8.54%). Adjuvant management demonstrated heterogeneity. Notably, there was no significant association between the continent and the offered adjuvant treatment for optimally cytoreduced stage III C LGSOC (p = 0.556; Fisher’s exact test). For recurrent disease, hormonal therapy (30.54%) and chemotherapy (27.59%) were common choices. MEK inhibitors were infrequently used. Fertility preservation was favored (71%), and HIPEC was not widely considered (81.28%). Genetic testing opinions varied: routine testing (28.7%), no recommendation (45.32%), and testing in recurrent settings (16.75%). Conclusion: This survey exposes global disparities in LGSOC management, highlighting the need for standardized guidelines to address challenges in diagnosis and management. International collaboration is advocated to enhance uniformity in healthcare practices for LGSOC.
- Open Access
- 28 July 2024
- Published by Elsevier in Gynecologic Oncology Reports
- Vol. 55, 101464
Vulvo-vaginal stromal tumours – Case series of a rare entity from an oncology centre in India
- 28 July 2024
- Published by Elsevier in Gynecologic Oncology Reports
- Vol. 55, 101464
Open AccessVulvo-vaginal stromal tumours – Case series of a rare entity from an oncology centre in India